Related Experiment Video
Updated: Apr 23, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Development of targeted near-infrared imaging agents for prostate cancer
Xinning Wang1, Steve S Huang2, Warren D W Heston3
1Department of Radiology and NFCR Center for Molecular Imaging, Case Western Reserve University, Cleveland, Ohio.
Abstract:
Prostate cancer is the most common noncutaneous malignancy affecting men in North America. Radical prostatectomy remains a definitive treatment for prostate cancer. However, prostate surgeries are still performed "blindly" with the extent of tumor infiltration past the margins of the surgery only being determined postoperatively. An imaging modality that can be used during surgery is needed to help define the tumor margins. With its abundant expression in prostate cancer, prostate-specific membrane antigen (PSMA) is an ideal target for detection of prostate cancer. The purpose of this study was to develop PSMA-targeted near-infrared (NIR) optical imaging probes for intraoperative visualization of prostate cancer. We synthesized a high-affinity PSMA ligand (PSMA-1) with low molecular weight and further labeled it with commercially available NIR dyes IRDy800 and Cy5.5. PSMA-1 and PSMA-1-NIR conjugates had binding affinities better than the parent ligand Cys-CO-Glu. Selective binding was measured for each of the probes in both in vitro and in vivo studies using competitive binding and uptake studies. Interestingly, the results indicated that the pharmacokinetics of the probes was dependent of the fluorophore conjugated to the PSMA-1 ligand and varied widely. These data suggest that PSMA-targeted probes have the potential to be further developed as contrast agents for clinical intraoperative fluorescence-guided surgery.
Insights
Researchers developed novel near-infrared imaging probes targeting prostate-specific membrane antigen (PSMA) for enhanced prostate cancer surgery. These PSMA-targeted probes show promise for real-time intraoperative visualization, improving surgical precision and outcomes.
Area of Science:
- Oncology
- Medical Imaging
- Biochemistry
Background:
- Prostate cancer is a leading malignancy in North America, often treated with radical prostatectomy.
- Current surgical procedures for prostate cancer lack real-time margin assessment, leading to postoperative determination of tumor infiltration.
- There is a critical need for intraoperative imaging modalities to define tumor margins during surgery.
Purpose of the Study:
- To develop prostate-specific membrane antigen (PSMA)-targeted near-infrared (NIR) optical imaging probes.
- To enable intraoperative visualization of prostate cancer during surgery.
- To assess the efficacy of these probes in defining tumor margins.
Main Methods:
- Synthesis of a high-affinity PSMA ligand (PSMA-1) with low molecular weight.
- Conjugation of PSMA-1 with commercially available NIR dyes (IRDy800 and Cy5.5).
- In vitro and in vivo evaluation of probe binding affinity, selectivity, and pharmacokinetics using competitive binding and uptake studies.
Main Results:
- PSMA-1 and its NIR conjugates demonstrated superior binding affinities compared to the parent ligand.
- Selective binding of the probes was confirmed in both in vitro and in vivo models.
- Probe pharmacokinetics varied significantly based on the conjugated fluorophore.
Conclusions:
- PSMA-targeted NIR probes show potential for intraoperative visualization of prostate cancer.
- These probes could serve as valuable contrast agents for fluorescence-guided surgery.
- Further development may lead to improved surgical precision and patient outcomes in prostate cancer treatment.
